Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:AstraZeneca
|
| gptkbp:acquisitionYear |
2021
|
| gptkbp:CEO |
gptkb:Ludwig_Hantson
|
| gptkbp:focusesOn |
rare diseases
|
| gptkbp:foundedIn |
1992
|
| gptkbp:founder |
gptkb:Leonard_Bell
|
| gptkbp:headquartersLocation |
gptkb:Boston,_Massachusetts,_United_States
New Haven, Connecticut, United States |
| https://www.w3.org/2000/01/rdf-schema#label |
Alexion
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Kanuma
gptkb:Soliris gptkb:Strensiq gptkb:Ultomiris |
| gptkbp:numberOfEmployees |
~3000
|
| gptkbp:stockSymbol |
gptkb:ALXN
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://alexion.com
|
| gptkbp:bfsParent |
gptkb:The_Sins_of_the_Night
|
| gptkbp:bfsLayer |
7
|